NBC Newsのインスタグラム(nbcnews) - 6月12日 23時02分

It sounds like a far-fetched dream: a vaccine that can delay the return of glioblastoma, one of the deadliest and treatment-resistant cancers.

The disease is devastating for patients and families; the five-year survival rate is 6.8%.

In an early clinical trial, SurVaxM was found to extend survival time for people diagnosed with the brain cancer to 26 months, on average.

Now the drugmaker, New York-based MimiVax, is enrolling patients in a larger trial, hoping to confirm the results.

Read more at the link in bio.

📷️ BSIP / Universal Images Group via @gettyimages

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する